Atlas Trials

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

Clinical trial NCT07131722 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07131722
Sponsor
PRG Science & Technology Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Neurofibromatosis Type IINF2
Start date
2026-07-01
Primary completion
2028-07-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.